SecBot SecBot
10-K/A ·Filed Apr 17, 2026

DAWN

Day One Biopharmaceuticals, Inc.
NEUTRAL
Impact 4/10
Horizonweeks Processed7mo ago SEC0001193125-26-161471
Amended annual report (potential restatement)
Actionable Insight • Neutral

The filing is procedurally significant but not financially transformative. Traders should focus on the pending Servier acquisition as the primary catalyst. The option repricing, while a negative signal about past stock performance, is a common retention tool in the biotech sector and should be viewed in the context of the company's acquisition. Monitor for the closing of the merger as the next major event.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$21.48
T+0 close · Apr 17, 2026 · via day close
Latest settled
+0.23%
T+5 · $21.53
Vs SPY
−0.68%
α at T+5
Next horizon
T+20
due 6mo ago
  1. T+0 · Apr 20 $21.48entry
  2. T+1 · 7mo ago +0.05%α +0.70% · $21.49
  3. T+5 · 7mo ago +0.23%α −0.68% · $21.53
  4. T+20 · due 6mo ago Pending
  5. T+60 · due 4mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

This is an amended 10-K filing by Day One Biopharmaceuticals to include Part II and Part III disclosures that were omitted from the original filing, primarily because the company did not intend to file a proxy statement within 120 days of its fiscal year-end. The amendment includes comprehensive details on executive compensation, board composition, director compensation, and equity plan information. A key event disclosed is the repricing of underwater stock options for executives and directors to $8.99 per share to retain talent, and the filing confirms the company's pending acquisition by Servier Pharmaceuticals.

Key Facts

  • The amendment was filed to include required Part II and Part III disclosures omitted from the original 10-K, not due to financial restatements or errors.
  • The company's pending acquisition by Servier Pharmaceuticals was announced on March 6, 2026, which explains the lack of a proxy statement.
  • An option repricing event occurred on November 6, 2025, reducing the exercise price of underwater options for executives and directors from prices as high as $23.41 to $8.99 per share, the then-current market price, to retain talent.
  • CEO Jeremy Bender's total compensation for 2025 was $9.1 million, with a CEO-to-median-employee pay ratio of 24:1.
  • The company has a $2.2B market cap and is headquartered in Brisbane, CA.

Financial Impact

The option repricing is a non-cash accounting event that resets the strike price of existing options. While it does not immediately dilute shareholders, it reduces the future value capture for the company if the stock price recovers, as employees can now exercise at a lower price. The total target equity value granted to the CEO in 2025 was $5.4 million.

dilutionexecutive compensationshareholder value

Risk Factors

  • The option repricing could be perceived negatively by shareholders as it rewards executives for poor stock performance, potentially leading to shareholder dissent.
  • The pending acquisition by Servier creates execution risk; the deal could fail to close due to regulatory or other issues.
  • The company reported a net loss of $107.3 million for 2025, which is a key financial risk factor.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
10-K/A Filing (Primary)0001193125-26-161471
Document: dawn-ex31_3.htm0001193125-26-161471
Document: dawn-ex31_4.htm0001193125-26-161471
Document: 0001193125-26-161471-index-headers.html0001193125-26-161471
Document: 0001193125-26-161471-index.html0001193125-26-161471
Document: 0001193125-26-161471.txt0001193125-26-161471

Track record

6 reports on DAWN

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. May 4, 202628w ago 15-12G Neutral 5/10 No price data
  2. Apr 23, 202629w ago 25-NSE Neutral 9/10 Entry $21.53 No price data
  3. Apr 23, 202629w ago 8-K Neutral 9/10 Entry $21.53 No price data
  4. Apr 17, 202630w ago 10-K/A Neutral 4/10 Viewing Entry $21.48 No price data
  5. Mar 6, 202636w ago Press Release Bullish 9/10 Entry $21.20 to $21.46 ▲ +1.23% +3.27% vs SPY
  6. Feb 24, 202637w ago 8-K Bullish 8/10 Entry $10.92 to $21.37 ▲ +95.79% +101.02% vs SPY
Showing 6 of 6

US Market Status

Market Closed · Opens in 6h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026